Research regenerative medicine gets an impulse
Starting 2017, health organizations, scientist, entrepreneurs and medical doctors will work together in the new institute RegMed XB (REGenerative MEDicine crossing Borders). The ambition of RegMed XB is to grow into a worldwide renowned innovation institute that accelerates the growth of a new industrial cluster, brings solutions for patients closer and contributes to affordable health care. The groups of prof. Carlijn Bouten, dr. dr. Patricia Dankers and prof. Keita Ito of the department of Biomedical Engineering at TU/e participate in this new collaboration.
Regenerative medicine aims to repair diseased or damaged tissues and organs. It offers the potential to cure what are now chronic diseases, and to reduce suffering and costs of healthcare. The ‘Nierstichting’, Diabetes Research Foundation Netherlands, ‘Diabetes Fonds’ and ‘Reumafonds’ intend to participate in RegMed XB to develop new treatments for patients with kidney diseases, diabetes type 1 and osteoarthritis.
RegMed XB will be further developed in 2016 and start in 2017 with a financial impulse of 18 million euro. The ambition is structural continuation with a target budget of 250 million euro for the first 10 years.
The Netherlands has a strong scientific track record in regenerative medicine. In RegMed XB, scientists and medical doctors from the universities and involved institutes from Utrecht, Maastricht, Leiden and Eindhoven and the academic hospitals in Utrecht, Maastricht and Leiden will work together. Collaboration with industry will enable the development of new high-quality industry. Therefore, the regional governments province of Utrecht, province of Noord-Brabant, province of Limburg and the city of Leiden also intend to support the collaboration. The new initiative already demonstrates its potential with 15 companies participating in the consortium. In a next phase, Belgian institutes will join the consortium.